|
Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis] |
Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Mengarelli C |
|
|
Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database. Citation Pichon Riviere A, Augustovski F, Garcia Marti S, Glujovsky D, Alcaraz A, Lopez A, Bardach A, Ciapponi A, Mengarelli C. Adalimumab, etanercept, infliximab y golimumab para el tratamiento de las espondilitis anquilosante y artritis reactiva. [Adalimumab, etanercept, infliximab and golimumab for the treatment of ankylosing spondylitis and reactive arthritis] Buenos Aires: Institute for Clinical Effectiveness and Health Policy (IECS). Informe de Respuesta Rápida N° 294. 2013 Authors' objectives To assess the available evidence on the efficacy, safety and coverage related issues on the use of Etarnercept, Adalimumab, Infliximab and Golimumab in patients with ankylosing spondylitis and reactive arthritis. Authors' conclusions The quality of the evidence found is high for ankylosing spondylitis and very low for reactive arthritis. Anti-TNF-alpha therapy has proved to better control ankylosing spondylitis inflammatory symptoms when compared to placebo or DMDs. The clinical practice guidelines recommend their use in patients refractory to standard therapy with active disease for over 4 weeks and a BASDAI score = or >4 (0–10). Patients with axial manifestations may start anti-TNF-alpha therapy without having previously received DMDs. In patients with peripheral arthritis, they are indicated after failure to sulfasalazine therapy. No evidence was found demonstrating anti-TNF-alpha efficacy in reactive arthritis. No evidence or recommendations were found comparing the relative effectiveness of the different anti-TNFs-alpha drugs. Indexing Status Subject indexing assigned by CRD MeSH Anti-Inflammatory Agents, Non-Steroidals; Immunosuppressive Agents; Spondylitis, Ankylosing Language Published Spanish Country of organisation Argentina English summary An English language summary is available. Address for correspondence Institute for Clinical Effectiveness and Health Policy, Viamonte 2146 - 3 Piso, C1056ABH Ciudad de Buenos Aires, Argentina Tel: +54 11 49 66 00 82 Fax:+54 11 49 53 40 58 Email: info@iecs.org.ar AccessionNumber 32014000269 Date abstract record published 28/01/2014 |
|
|
|